Forced Degradation Study

A forced degradation study exposes the drug substance and product to conditions far harsher than storage, making degradation happen quickly and deliberately. The standard stresses are acid and base hydrolysis, peroxide oxidation, dry and humid heat, and a defined photostability exposure. The purpose is twofold: to identify what the molecule turns into, and to show the method resolves each of those products from the parent peak. A method that does this is stability-indicating, a term empty without the stress data behind it.

The target is partial degradation, conventionally five to twenty percent; complete destruction produces secondary products never on the real pathway. For peptides the pathways are predictable from the sequence: deamidation at asparagine-glycine, oxidation at methionine and tryptophan, hydrolysis at aspartate-proline, disulfide scrambling and aggregation. Mass balance is checked too, since a degradant that neither absorbs at the detection wavelength nor elutes in the run window would vanish from the accounting.

This is what gives a shelf-life claim its foundation. Without it there is no evidence the method would even see the degradant that actually forms, and a method co-eluting the parent with its deamidated form will report full purity on a substantially degraded sample. It is not a shelf-life measurement: it validates a method and maps chemistry, while shelf life comes from real-time and accelerated studies on the formulation itself.

The interpretive error runs both ways. Treating an hour under peroxide as a prediction of what a refrigerated vial does over two years reads a probe as a forecast, which it is not. Conversely, room-temperature claims on grey-market peptides rest on neither stress testing nor real-time data, and a purity figure from a method never shown to separate degradants is the weaker claim, not the stronger.